HK1003938A1 - Thiazole derivatives as active oxygen inhibitors - Google Patents

Thiazole derivatives as active oxygen inhibitors

Info

Publication number
HK1003938A1
HK1003938A1 HK98103139A HK98103139A HK1003938A1 HK 1003938 A1 HK1003938 A1 HK 1003938A1 HK 98103139 A HK98103139 A HK 98103139A HK 98103139 A HK98103139 A HK 98103139A HK 1003938 A1 HK1003938 A1 HK 1003938A1
Authority
HK
Hong Kong
Prior art keywords
active oxygen
thiazole derivatives
oxygen inhibitors
inhibitors
thiazole
Prior art date
Application number
HK98103139A
Other languages
English (en)
Inventor
Masatoshi Chihiro
Hajime Komatsu
Michiaki Tominaga
Youichi Yabuuchi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1003938A1 publication Critical patent/HK1003938A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
HK98103139A 1990-11-30 1998-04-16 Thiazole derivatives as active oxygen inhibitors HK1003938A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33772790 1990-11-30
PCT/JP1991/001659 WO1992009586A1 (en) 1990-11-30 1991-11-29 Active oxygen inhibitor

Publications (1)

Publication Number Publication Date
HK1003938A1 true HK1003938A1 (en) 1998-11-13

Family

ID=18311399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103139A HK1003938A1 (en) 1990-11-30 1998-04-16 Thiazole derivatives as active oxygen inhibitors

Country Status (11)

Country Link
US (4) US5643932A (xx)
EP (3) EP0934937B1 (xx)
JP (2) JP2829451B2 (xx)
KR (2) KR100195433B1 (xx)
CA (3) CA2396738C (xx)
DE (3) DE69132944T2 (xx)
DK (3) DK0934937T3 (xx)
ES (3) ES2144403T3 (xx)
HK (1) HK1003938A1 (xx)
TW (1) TW311136B (xx)
WO (1) WO1992009586A1 (xx)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657413C (en) * 1992-05-29 2007-05-03 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives for the release of superoxide radical
US5639770A (en) * 1992-05-29 1997-06-17 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives
NZ255580A (en) * 1992-09-14 1997-08-22 Yamanouchi Pharma Co Ltd 2-(imidazolyl)alkylene-condensed thiazole derivatives and pharmaceutical compositions
EP0637588A4 (en) * 1993-01-19 1995-12-13 Shiseido Co Ltd INHIBITOR OF ACTIVE OXYGEN.
US5834499A (en) * 1994-03-11 1998-11-10 Yamanouchi Pharmaceutical Co., Ltd. 5-HT3 receptor agonist, novel thiazole derivative and intermediate thereof
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
ATE252560T1 (de) * 1994-12-22 2003-11-15 Ligand Pharm Inc Steroidrezeptor-modulator verbindungen und methoden
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
US5693647A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JP3896552B2 (ja) * 1996-03-25 2007-03-22 大塚製薬株式会社 チアゾール誘導体−金属錯体
AU4298997A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
WO1998008841A1 (de) * 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue thiazol-derivate mit phosphodiesterase inhibierender wirkung
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
JP4305662B2 (ja) * 1996-09-30 2009-07-29 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
JP4305668B2 (ja) * 1996-09-30 2009-07-29 大塚製薬株式会社 サイトカイン異常産生又は接着作用の亢進に伴う疾患を予防又は治療するための薬剤
JP4300373B2 (ja) * 1996-09-30 2009-07-22 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
EP0941226A1 (de) * 1996-11-12 1999-09-15 Byk Gulden Lomberg Chemische Fabrik GmbH (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO1998028282A2 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
ZA985251B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Inhibitors of factor Xa with a neutral P1 specificity group.
ES2239806T3 (es) * 1997-06-19 2005-10-01 Bristol-Myers Squibb Pharma Company Inhibidores del factor xa con un grupo de especificidad neutro p1.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
KR100404358B1 (ko) 1998-01-28 2003-11-03 시오노기세이야쿠가부시키가이샤 신규 삼환식 화합물
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
US6322449B1 (en) 1998-02-04 2001-11-27 Klitsner Industrial Design, Llc Mechanical interface device
AU4394799A (en) 1998-07-01 2000-01-24 Takeda Chemical Industries Ltd. Retinoid-associated receptor regulators
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
NZ526880A (en) * 1998-09-21 2005-05-27 Univ Florida Antimalarial agents
JP4336913B2 (ja) * 1999-02-12 2009-09-30 大塚製薬株式会社 アミド誘導体の製造方法
JP2000281664A (ja) * 1999-03-30 2000-10-10 Otsuka Pharmaceut Co Ltd チアゾール誘導体
EP1175419B1 (en) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
DE60024861T2 (de) * 1999-10-28 2006-07-06 Trine Pharmaceuticals, Inc., Waltham Pumpeninhibitoren zur freisetzung von medikamenten
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
ES2309095T3 (es) * 2000-10-02 2008-12-16 Janssen Pharmaceutica Nv Antagonistas de los receptores metabotropicos de glutamato.
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
DE10102084B4 (de) * 2001-01-18 2006-06-29 Wella Ag 1,4-Diamino-2-(thiazol-2-yl)-benzol-Derivate enthaltende Haarfärbemittel
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
CA2445697A1 (en) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
BR0208719A (pt) 2001-07-24 2004-07-20 Otsuka Pharma Co Ltd Uso de um composto
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
FR2835254B1 (fr) * 2002-01-25 2006-04-07 Sod Conseils Rech Applic Derives de thiazoles dans le traitement de maladies neurologiques
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
WO2004024061A2 (en) * 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
US20050165011A1 (en) * 2002-05-15 2005-07-28 Gellibert Francoise J. Benzoxazine and benzoxazinone substituted triazoles
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003263948A1 (en) * 2002-08-22 2004-03-11 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
MXPA05010945A (es) * 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
TW200503700A (en) * 2003-07-17 2005-02-01 Otsuka Pharma Co Ltd Enema preparation
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP4879165B2 (ja) * 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
CN1953968B (zh) * 2004-05-17 2012-10-10 大塚制药株式会社 噻唑化合物及其用途
CN101189216B (zh) 2005-04-04 2011-10-19 佛罗里达大学研究基金会 Desferrithiocin聚醚类似物
CN101282936B (zh) * 2005-10-07 2012-05-16 橘生药品工业株式会社 氮化杂环化合物及包含其的药物组合物
US20090253687A1 (en) * 2005-12-28 2009-10-08 Shoji Fukumoto Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
TWI436761B (zh) 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
CN102772411A (zh) 2006-07-05 2012-11-14 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EP2120580B1 (en) 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
AU2008229472B2 (en) * 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
HUE027022T2 (en) 2007-08-13 2016-08-29 Monsanto Technology Llc Preparations and procedures for controlling nematodes
ES2591028T3 (es) * 2007-09-06 2016-11-24 Boston Biomedical, Inc. Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas
EP3289876B1 (en) * 2008-06-16 2022-07-20 University of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
JP2012501334A (ja) * 2008-08-29 2012-01-19 トランス テック ファーマ，インコーポレイテッド 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1P RECEPTOR MODULATORS
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
CA2837268C (en) * 2011-06-07 2020-05-12 Oren M. Becker Compositions and methods for modulating a kinase
WO2012170371A1 (en) * 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
ES2609459T3 (es) * 2012-08-23 2017-04-20 The Institute Of Cancer Research : The Royal Cancer Hospital Compuestos heterocíclicos condensados y su uso
WO2014074926A1 (en) * 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
KR102246652B1 (ko) 2013-03-05 2021-04-29 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
US9408796B2 (en) 2013-03-13 2016-08-09 Avon Products, Inc Cosmetic compositions for improving the appearance of skin
CA2922703A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
RU2017125663A (ru) 2014-12-19 2019-01-21 Галдерма Ресерч Энд Девелопмент Новые соединения, способ их синтеза и их применение в медицине, а также в косметике
AU2016255770A1 (en) 2015-04-27 2017-11-16 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
KR20240118600A (ko) 2023-01-27 2024-08-05 이택종 분자수소를 유효성분으로 함유하는 항산화 건강보조식품

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1970656A (en) * 1931-11-04 1934-08-21 Winthrop Chem Co Inc Thiazole compound and process of producing the same
NL284415A (xx) * 1961-10-19
JPS3910130B1 (xx) * 1962-05-10 1964-06-10
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3401120A (en) * 1965-10-23 1968-09-10 Gaf Corp Corrosion inhibitors
GB1139940A (en) * 1966-09-30 1969-01-15 Ici Ltd Oxazole derivatives
DE1670383A1 (de) * 1966-09-14 1970-10-29 Ciba Geigy Neue Tetrahydroimidazole und Verfahren zu ihrer Herstellung
US3462448A (en) * 1966-10-27 1969-08-19 Dow Chemical Co Substituted phenyl thiazole compounds
IL28803A (en) * 1966-11-18 1974-05-16 Wyeth John & Brother Ltd Oxazole and thiazole compounds,their preparation and pharmaceutical compositions containing them
GB1226548A (xx) * 1967-06-14 1971-03-31 Wyeth John & Brother Ltd
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3625999A (en) * 1968-02-19 1971-12-07 Lever Brothers Ltd Process for the preparation of phosphonium sulfonate salts
FR96117E (fr) * 1968-03-28 1972-05-19 Aquitaine Petrole Synthese d'oxazoles.
CY800A (en) * 1968-04-09 1976-12-01 Wyeth John & Brother Ltd Novel thiazoline derivatives, the preparation thereof and compositions containing the same
GB1248070A (en) * 1968-12-16 1971-09-29 Science Union & Cie Thiazolyl-benzoic acid derivatives and process for preparing them
US4001420A (en) * 1968-12-12 1977-01-04 Science Union Et Cie, Societe Francaise De Recherche Medical Thiazolyl benzoic acid compounds
US3635999A (en) 1969-03-25 1972-01-18 Aquitaine Petrole Synthesis of oxazoles
JPS4637822B1 (xx) * 1969-05-31 1971-11-08
US3705153A (en) * 1969-05-14 1972-12-05 Sumitomo Chemical Co Novel thiazolyacetic acids and salts thereof
JPS4624696B1 (xx) * 1969-06-30 1971-07-15
FR2082164A5 (en) * 1970-03-05 1971-12-10 Aries Robert Phenylalkyl esters of oxazolyl and thiazolyl carboxylic - acids - analgesics, antiinflammatories, tranquilisers
GB1308028A (en) * 1970-06-12 1973-02-21 Science Union & Cie Thiazolylbenzoic acid derivatives and a process for their manufactur
DE2048272C3 (de) * 1970-10-01 1974-10-17 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von 1,1,2-Trimethoxyäthanund o-Essigsäuremethylester
CA962269A (en) 1971-05-05 1975-02-04 Robert E. Grahame (Jr.) Thiazoles, and their use as insecticides
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
JPS471469A (xx) * 1971-06-22 1972-01-25
DE2152367C2 (de) * 1971-10-21 1985-01-03 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 4- Methyl-oxazolen
BE791087A (fr) * 1971-11-15 1973-03-01 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
BE794096A (fr) * 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
JPS4938268A (xx) * 1972-08-16 1974-04-09
JPS4938267A (xx) * 1972-08-18 1974-04-09
JPS5327586B2 (xx) * 1972-08-23 1978-08-09
JPS503315A (xx) * 1973-05-10 1975-01-14
US4072689A (en) * 1973-02-22 1978-02-07 Gruppo Lepetit S.P.A. Monoamino 2,4,5-trisubstituted oxazoles
JPS5030619A (xx) * 1973-07-23 1975-03-26
HU168036B (xx) * 1973-11-09 1976-02-28
DE2711655A1 (de) * 1977-03-17 1978-09-21 Basf Ag Pyridinyl-aminoalkylaether
US4259341A (en) * 1977-06-01 1981-03-31 Merck & Co., Inc. Di- and tri-substituted thiazoles
US4153703A (en) * 1977-06-30 1979-05-08 Uniroyal, Inc. Method of controlling insects and acarids with certain aryl-substituted thiazoles
JPS5461936A (en) * 1977-10-26 1979-05-18 Ricoh Co Ltd Photoreceptor for electrophotography
JPS6051475B2 (ja) * 1977-11-08 1985-11-14 久光製薬株式会社 新規なフエニル酢酸誘導体
GB1574583A (en) * 1978-02-09 1980-09-10 Wyeth John & Brother Ltd Process for preparing thiazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4221584A (en) * 1979-02-09 1980-09-09 Chevron Research Company Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
JPS55111418A (en) * 1979-02-21 1980-08-28 Santen Pharmaceut Co Ltd Remedy for eye disease and its preparation
AU534093B2 (en) * 1979-03-19 1984-01-05 Ici Australia Limited Thiazoles,benzthiazoles, benzoxazoles and benzimidazoles
NZ193011A (en) * 1979-03-19 1983-03-15 Ici Australia Ltd Diarylamine derivatives intermediates herbicidal compositions
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
US4298743A (en) * 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
JPS56123544A (en) * 1980-03-03 1981-09-28 Hitachi Ltd Composite type electrophotographic plate and electrophotographic method using it
US4322428A (en) * 1980-04-02 1982-03-30 Eli Lilly And Company 2(4-Fluorophenyl)-4,5,-bis(4-methoxyphenyl)thiazole and method of use
ZA811691B (en) * 1980-04-03 1982-10-27 Wyeth John & Brother Ltd Thiazoles
US4329459A (en) * 1980-05-05 1982-05-11 The Upjohn Company Tetrahydrobenzopyran derivatives
US4282364A (en) * 1980-05-22 1981-08-04 Merck & Co., Inc. Process for the preparation of thiazoles
JPS58120257A (ja) * 1982-01-12 1983-07-18 Hitachi Chem Co Ltd 電子写真感光体
DD204094A1 (de) * 1982-02-11 1983-11-16 Horst Hartmann Verfahren zur herstellung von 2-aryl-4-cumaryl-(3')- bzw. 2,4-bis-cumaryl-(3')-thiazolen
JPS58201771A (ja) * 1982-05-19 1983-11-24 Tanabe Seiyaku Co Ltd アルキルオキサゾリル酢酸誘導体
JPS58219169A (ja) * 1982-06-15 1983-12-20 Takeda Chem Ind Ltd オキサゾ−ル酢酸誘導体
JPS5925381A (ja) * 1982-06-30 1984-02-09 Hisamitsu Pharmaceut Co Inc 新規なフエニル酢酸誘導体
JPS5925380A (ja) * 1982-06-30 1984-02-09 Hisamitsu Pharmaceut Co Inc 新規なフエニル酢酸誘導体
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
JPS6051111A (ja) * 1983-08-30 1985-03-22 Tanabe Seiyaku Co Ltd 抗脂血剤
JPS60151045A (ja) * 1984-01-19 1985-08-08 富士写真フイルム株式会社 感光材料用包装材料
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS6133186A (ja) * 1984-07-25 1986-02-17 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
JPS61200985A (ja) * 1985-02-28 1986-09-05 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
US4659726A (en) * 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
JPS60222481A (ja) * 1984-04-19 1985-11-07 Kanebo Ltd 新規なジフエニルピロリルチアゾ−ル誘導体、その製造法およびそれを有効成分とする医薬組成物
JPS60230147A (ja) * 1984-04-27 1985-11-15 Ricoh Co Ltd 電子写真製版用印刷原版
DE3425118A1 (de) * 1984-07-07 1986-01-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
JPS6123790A (ja) * 1984-07-12 1986-02-01 Hitachi Cable Ltd ＮｉまたはＮｉ合金表面へのメツキ方法
DE3501696A1 (de) * 1985-01-19 1986-07-24 Bayer Ag, 5090 Leverkusen Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3525689C1 (de) * 1985-07-18 1986-10-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren und Einrichtung zum Betrieb eines mit einer Protonenuebertragungsreaktion arbeitenden Farbstoff-Lasers
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
DE3601411A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 3-amino-1-(2-thiazolyl)-2-pyrazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
KR900000566B1 (ko) * 1986-04-30 1990-01-31 에프 엠 씨 코포레이션 광활성 아졸 살충제
JPH075579B2 (ja) * 1986-09-01 1995-01-25 吉富製薬株式会社 アミノチアゾ−ル化合物
JPS63192755A (ja) * 1987-02-06 1988-08-10 Fujisawa Pharmaceut Co Ltd ２−フエニルアゾ−ル誘導体およびその塩
US4791200A (en) * 1987-06-22 1988-12-13 Ortho Pharmaceutical Corporation 2-substituted-4-aryl-substituted thiazoles
JPS6422861A (en) * 1987-07-18 1989-01-25 Kirin Brewery New substance ag55-2
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
JPH02171280A (ja) * 1988-12-26 1990-07-02 Agency Of Ind Science & Technol インクジェット用蛍光性インク組成物
DE3929233A1 (de) 1989-09-02 1991-03-07 Bayer Ag 5-heterocyclyl-pyridin-3-carbon-benzylamide und -anilide
AU621245B2 (en) * 1989-10-17 1992-03-05 Boehringer Mannheim Gmbh Hydrolase substrates, a process for the preparation thereof and agents containing them

Also Published As

Publication number Publication date
KR100249545B1 (en) 2000-04-01
CA2074933C (en) 2002-12-03
DE69132006T2 (de) 2000-08-03
EP1130017B1 (en) 2005-06-15
JP2829451B2 (ja) 1998-11-25
AU8936791A (en) 1992-06-25
EP0513387A4 (en) 1993-04-21
DE69132006D1 (de) 2000-04-06
DK1130017T3 (da) 2005-10-10
EP0513387A1 (en) 1992-11-19
CA2074933A1 (en) 1992-05-31
ES2144403T3 (es) 2000-06-16
DE69132944T2 (de) 2002-11-21
CA2396738C (en) 2006-08-29
AU656930B2 (en) 1995-02-23
CA2547947C (en) 2007-09-25
EP0934937A1 (en) 1999-08-11
DK0513387T3 (da) 2000-06-05
DK0934937T3 (da) 2002-04-02
CA2547947A1 (en) 1992-06-25
US5643932A (en) 1997-07-01
KR927003551A (ko) 1992-12-18
DE69132944D1 (de) 2002-04-04
DE69133471T2 (de) 2006-05-11
ES2245660T3 (es) 2006-01-16
US5677319A (en) 1997-10-14
USRE37556E1 (en) 2002-02-19
EP0934937B1 (en) 2002-02-27
EP0513387B1 (en) 2000-03-01
ES2173683T3 (es) 2002-10-16
US6080764A (en) 2000-06-27
DE69133471D1 (de) 2005-07-21
EP1130017A3 (en) 2001-09-19
CA2396738A1 (en) 1992-06-25
JPH0551318A (ja) 1993-03-02
WO1992009586A1 (en) 1992-06-11
TW311136B (xx) 1997-07-21
EP1130017A2 (en) 2001-09-05
KR100195433B1 (ko) 1999-06-15
JPH10101562A (ja) 1998-04-21
JP3182556B2 (ja) 2001-07-03

Similar Documents

Publication Publication Date Title
HK1003938A1 (en) Thiazole derivatives as active oxygen inhibitors
EP0468339A3 (en) Alpha-keto-amide derivatives having protease inhibiting activity
HU0500355D0 (en) Substituted thiazolidinedione derivatives
EP0586537A4 (en) Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
ZA917003B (en) Novel thiazolidine derivatives
ZA891681B (en) Thiazolidinedione derivatives as hypoglycemic agents
GB9204958D0 (en) Thiazole derivatives
EP0542630A3 (en) Use of derivatives of amphotericin b as protease inhibitors
GB9102804D0 (en) Heterocyclic derivatives
ZA898292B (en) Thiazole derivatives
EP0519370A3 (en) Heterocyclic derivatives
IL110280A0 (en) Thiazole derivatives
ZA91418B (en) Thiazole derivatives
AU656930C (en) Active oxygen inhibitor
HU9400358D0 (en) Use of quinoziline derivatives as orexigenics
IE901154L (en) Thioformamide derivatives
GB9028059D0 (en) Thiazole derivatives
GB9003347D0 (en) Thiazole derivatives
GB9127530D0 (en) Thiazole derivatives
IE883766L (en) Thioformamide derivatives
IE881777L (en) Thiazolidinedione derivatives
IL92056A0 (en) Herbicidal compositions containing thiazole derivatives
GB9203809D0 (en) Heterocyclic derivatives
IE881919L (en) Thiazole derivatives
GB9110593D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20111128